1
|
Shettima FB, Wakil MA, Sheikh TL, Abdulaziz M, Rabbebe IB, Wakawa IA, Placidus O. Prevalence and correlates of sexual dysfunction among patients with schizophrenia spectrum disorder on antipsyhotic medications in Maiduguri, Northeastern Nigeria. Int J Psychiatry Med 2024; 59:373-392. [PMID: 37616598 DOI: 10.1177/00912174231196612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 08/26/2023]
Abstract
OBJECTIVES Despite the importance of a satisfying sexual life, most patients with schizophrenia spectrum disorders do not discuss sexual issue with their clinicians. The current study seeks to determine the prevalence and socio-clinical correlates of sexual dysfunction among patients with schizophrenia spectrum disorders receiving typical and atypical antipsychotic medications. The second objective is to determine the frequency and correlates of specific sexual dysfunction (desire, arousal, erection/lubrication and orgasm) by gender and drug type using the Arizona Sexual Experience Scale. METHODOLOGY This cross-sectional study used standardized structured interviewer based survey to assess sexual dysfunction among patients with schizophrenia that are both sexually active and inactive at a tertiary hospital in Maiduguri from December 2020 to April 2021. Participants were also assayed for prolactin using ELISA Kit for a possible association with sexual dysfunction. RESULTS The overall prevalence of sexual dysfunction among patients with schizophrenia spectrum disorder receiving antipsychotics was 34% with patients on typical and atypical antipsychotics reporting rates of 36.8% and 24.6%, respectively. Among the typical and atypical antipsychotics, patients receiving haloperidol (40.3%) and risperidone (37.5%) reported a relatively higher frequency of sexual dysfunction compared to those receiving clozapine (18.2%). Independent correlates of sexual dysfunction were: female gender (OR = 1.89, 95% CI = 1.17-3.06; P = .010), being unmarried (OR = 1.51, 95% CI = 1.17-1.96; P = .001), pseudoparkinsonism (OR = 1.66, 95% CI = 1.02-2.69; P = .008), prolactin (OR = 2.15, 95% CI = 1.34-3.43; P = .001) and severity of illness (OR = 1.34, 95% CI = 1.03-1.75; P = .030). CONCLUSION Sexual dysfunction is prevalent among patients with schizophrenia spectrum disorder receiving either typical or atypical antipsychotics.
Collapse
Affiliation(s)
- Falmata Baba Shettima
- Departmental of Mental Health, Federal Neuropsychiatric Hospital Maiduguri, Maiduguri, Nigeria
| | - Musa Abba Wakil
- Departmental of Mental Health, Federal Neuropsychiatric Hospital Maiduguri, Maiduguri, Nigeria
| | | | | | - Isa Bukar Rabbebe
- Departmental of Mental Health, Federal Neuropsychiatric Hospital Maiduguri, Maiduguri, Nigeria
| | - Ibrahim Abdu Wakawa
- Departmental of Mental Health, Federal Neuropsychiatric Hospital Maiduguri, Maiduguri, Nigeria
| | - Ogualili Placidus
- Departmental of Mental Health, Federal Neuropsychiatric Hospital Maiduguri, Maiduguri, Nigeria
| |
Collapse
|
2
|
Naguy A. Psychotropic-Related Sexual Dysfunction: Clinical Insights. Prim Care Companion CNS Disord 2023; 25:23lr03609. [PMID: 38134397 DOI: 10.4088/pcc.23lr03609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2023] Open
Affiliation(s)
- Ahmed Naguy
- Al-Manara CAP Centre, Kuwait Centre for Mental Health, Jamal Abdul-Nassir St, Shuwaikh
- Corresponding Author: Ahmed Naguy, MBBch, MSc, MRCPsych (UK), Al-Manara CAP Centre, Kuwait Centre for Mental Health, Jamal Abdul-Nassir St, Shuwaikh, Sulibikhat, 21315 Kuwait
| |
Collapse
|
3
|
Petrova NN. [Sexual dysfunction on the background of antidepressant therapy]. Zh Nevrol Psikhiatr Im S S Korsakova 2023; 123:115-121. [PMID: 38127711 DOI: 10.17116/jnevro2023123112115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2023]
Abstract
The review is devoted to the problem of sexual dysfunction caused by taking antidepressants. Sexual dysfunction is widespread, but it is not reported, and its impact on the quality of life and compliance of patients is underestimated. Partly because of its bidirectional association with depression, sexual dysfunction is difficult to diagnose. Possible mechanisms and risk factors associated with sexual dysfunction in patients with depression are considered. The data on the frequency of sexual dysfunction with the use of various antidepressants are given. Therapeutic strategies for sexual dysfunction associated with taking antidepressants are described. The advantages of agomelatin as an antidepressant associated with a low risk of sexual side effects are emphasized.
Collapse
Affiliation(s)
- N N Petrova
- Saint Petersburg State University, St. Petersburg, Russia
| |
Collapse
|
4
|
Suwarno S, Vedula S, Shah N, Artounian K, Petty A. Lamotrigine-Induced Persistent Genital Arousal Disorder and a Potential Treatment. J Sex Marital Ther 2022; 49:96-98. [PMID: 35575043 DOI: 10.1080/0092623x.2022.2073931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Persistent Genital Arousal Disorder (PGAD) is a rare disorder characterized by involuntary genital arousal without relief after orgasm or subjective feelings of sexual excitement. There is sparse data for effective treatments of PGAD, which can cause significant distress, anxiety, and depression for patients. We present a case of a patient with major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) who was diagnosed with PGAD shortly after she was started on lamotrigine for mood stabilization. Inpatient psychiatric treatment with increasing doses of sertraline resulted in reduction of her symptoms, suggesting its possible role in PGAD treatment and management.
Collapse
Affiliation(s)
- Serena Suwarno
- University of Arizona College of Medicine-Phoenix, Phoenix, AZ, USA
| | - Samhita Vedula
- University of Arizona College of Medicine-Phoenix, Phoenix, AZ, USA
| | - Neet Shah
- Department of Psychiatry, Banner University Medical Center-Phoenix, Phoenix, AZ, USA
| | - Kim Artounian
- University of Arizona College of Medicine-Phoenix, Phoenix, AZ, USA
| | - Alena Petty
- Department of Psychiatry, Banner University Medical Center-Phoenix, Phoenix, AZ, USA
| |
Collapse
|
5
|
Abstract
Objective: To examine the association between sexual functioning, depression and anxiety severity, and selective serotonin reuptake inhibitor (SSRI) use in adolescents. Methods: From September 2010 to December 2014, 15- to 20-year-old participants, either unmedicated or within a month of beginning SSRI treatment, completed the Beck Depression Inventory-II (BDI-II), Beck Anxiety Inventory (BAI), and Changes in Sexual Functioning Questionnaire (CSFQ) at baseline and every 4 months for up to 2 years. The DSM-IV-TR was used to determine presence of psychiatric disorders. Data regarding use of medications and hormonal contraception were collected. Polymorphisms of the HTR2A and ABCB1 genes were genotyped. Linear mixed-effects regression models examined the association between depression and anxiety symptom severity, SSRI use, and sexual functioning, accounting for relevant covariates. Results: A total of 263 participants (59% female, mean ± SD age = 18.9 ± 1.6 years, 70% with major depressive disorder) contributed to this analysis. After adjusting for age, sex, and duration in the study, depression severity, but not anxiety severity, was associated with lower CSFQ total scores (β = -0.13, P < .0001) and lower arousal, orgasm, and pleasure subscale scores (all β = -0.03, P < .003). Higher SSRI doses were associated with lower orgasm subscale scores (β = -0.30, P < .03). Hormonal contraceptive use was associated with higher CSFQ total scores (β = 0.97, P < .003) and higher arousal (β = 0.25, P < .009), desire (β = 0.24, P < .001), orgasm (β = 0.27, P < .02), and pleasure (β = 0.15, P < .004) subscale scores. No significant genetic moderating effect was found. Conclusions: In adolescents, depression is associated with lower sexual functioning while SSRI use impairs orgasm.
Collapse
Affiliation(s)
- Emira Deumic Shultz
- Department of Psychiatry, University of Iowa Hospitals and Clinics, Iowa City, Iowa
| | - James A Mills
- Department of Psychiatry, University of Iowa Hospitals and Clinics, Iowa City, Iowa
| | - Vicki L Ellingrod
- Clinical and Translational Pharmacy, College of Pharmacy; Departments of Psychiatry and Psychology; Michigan Institute for Clinical and Health Research (MICHR); and Education and Mentoring Group, University of Michigan, Ann Arbor, Michigan
| | - Jeffrey R Bishop
- Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, Minnesota
- Department of Psychiatry, University of Minnesota Medical School, Minneapolis, Minnesota eMenninger Department of Psychiatry and Behavioral Sciences and Department of Pediatrics, Baylor College of Medicine-Texas Children's Hospital, Houston, Texas *Corresponding author: Chadi A. Calarge, MD, 1102 Bates Ave, Ste 790, Houston, TX 77030
| | - Chadi A Calarge
- Menninger Department of Psychiatry and Behavioral Sciences and Department of Pediatrics, Baylor College of Medicine-Texas Children's Hospital, Houston, Texas
- Corresponding author: Chadi A. Calarge, MD, 1102 Bates Ave, Ste 790, Houston, TX 77030
| |
Collapse
|
6
|
Abstract
The present paper is describing a case of persistent genital arousal disorder that developed to a 55-year-old woman, shortly after the initiation of zolpidem. Persistent genital arousal disorder (PGAD) is a clinical entity that appears with a relatively low frequency in women, and is characterized by persistent or recurrent, unwanted and bothersome feelings of genital arousal, which often do not resolve with orgasm and are not associated with sexual desire (sexual interest, thoughts or fantasies). Women who experience PGAD often have feelings of shame, guilt and distress. Although its exact etiology remains unclear, various etiological factors have been proposed, central or peripheral, which may be psychological, vascular, dietary, pharmacological or neurological. Additionally, its presence has been associated to restless legs syndrome and overactive bladder syndrome. Likewise, multiple therapeutic interventions have been proposed and tried in patients with PGAD, either pharmacological (SSRIs, SNRIs, antiandrogens, benzodiazepines, antipsychotics, anticonvulsive agents) or other (ECT, physiotherapy, psychotherapy, nerve stimulation). Zolpidem is a nonbenzodiazepine indirect GABA A receptor agonist, which has lately been used as a therapeutic agent for PGAD in some cases. Nevertheless, in our patient, receiving zolpidem for insomnia seemed to be timely connected to the onset of PGAD symptomatology. The aim of the present paper is to highlight the need for more research into the possible factors that may contribute to PGAD.
Collapse
Affiliation(s)
- F Ferenidou
- Outpatient Clinic for Psychosexual Disorders, 1st Department of Psychiatry, University of Athens Medical School, Eginition Hospital, Greece
| | - I Mourikis
- Outpatient Clinic for Psychosexual Disorders, 1st Department of Psychiatry, University of Athens Medical School, Eginition Hospital, Greece
| | - P Sotiropoulou
- Outpatient Clinic for Psychosexual Disorders, 1st Department of Psychiatry, University of Athens Medical School, Eginition Hospital, Greece
| | - N Vaidakis
- Outpatient Clinic for Psychosexual Disorders, 1st Department of Psychiatry, University of Athens Medical School, Eginition Hospital, Greece
| |
Collapse
|
7
|
Montejo AL, Calama J, Rico-Villademoros F, Montejo L, González-García N, Pérez J. A Real-World Study on Antidepressant-Associated Sexual Dysfunction in 2144 Outpatients: The SALSEX I Study. Arch Sex Behav 2019; 48:923-933. [PMID: 30790204 DOI: 10.1007/s10508-018-1365-6] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/19/2017] [Revised: 11/07/2018] [Accepted: 11/28/2018] [Indexed: 06/09/2023]
Abstract
The objective of this cross-sectional study was to evaluate the frequency, impact, and management of sexual dysfunction associated with commonly prescribed antidepressants available in psychiatry outpatient clinics in Spain. We recruited 2163 adult patients who had undergone treatment with antidepressants for at least 8 weeks and had a history of normal sexual functioning before the prescription of the antidepressant, except for mildly impaired libido. We used the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) for evaluating the frequency and tolerance of sexual dysfunction and whether this side effect was spontaneously reported. Overall, 79% patients showed sexual dysfunction, as indicated by a total score ≥ 3 on the PRSexDQ-SALSEX; 64% showed moderate-severe sexual dysfunction, with no differences between men and women on these outcomes. In the multivariate logistic regression analysis, treatment with a serotonergic antidepressant and having a severe clinical state of psychiatric illness were the factors associated with the highest likelihood of presenting with sexual dysfunction. Sexual dysfunction was spontaneously reported by 838 (41%) of the 2066 evaluable patients for this outcome. Among patients with sexual dysfunction, this condition was poorly tolerated by 22% of the patients, with these frequencies being significantly higher in men than in women. The most frequently used strategies employed by the psychiatrists in our study for dealing with sexual dysfunction were switching to another antidepressant (34%) and waiting for spontaneous resolution (33%). In conclusion, our results indicate that despite being a well-known, long-standing side effect of antidepressants, sexual dysfunction continues to be extremely common in patients receiving antidepressants, especially serotonergic ones, potentially jeopardizing treatment success in a substantial proportion of patients. There are important sex differences in the reporting and tolerance of sexual dysfunction that require further investigation.
Collapse
Affiliation(s)
- Angel L Montejo
- Neurosciences Area, Instituto de Investigación Biomédica de Salamanca, University of Salamanca, Salamanca, Spain.
- Psychiatry Department, University Hospital of Salamanca, Paseo de San Vicente, 58-182, 37007, Salamanca, Spain.
| | - Julia Calama
- Neurosciences Area, Instituto de Investigación Biomédica de Salamanca, University of Salamanca, Salamanca, Spain
- Psychiatry Department, University Hospital of Salamanca, Paseo de San Vicente, 58-182, 37007, Salamanca, Spain
| | | | - Laura Montejo
- Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Centro de Investigación Biomédica en Red de Salud Mental, Barcelona, Spain
| | - Nerea González-García
- Neurosciences Area, Instituto de Investigación Biomédica de Salamanca, University of Salamanca, Salamanca, Spain
- Department of Statistics, School of Medicine, University of Salamanca, Salamanca, Spain
| | - Jesús Pérez
- Department of Psychiatry, University of Cambridge, Cambridge, UK
| |
Collapse
|
8
|
van Berkel A, Seldenrijk A, Knegtering H, Bakker PR, Ruhé HG, Kramers C. [Sexual dysfunction as a side effect of medication]. Ned Tijdschr Geneeskd 2018; 162:D2749. [PMID: 30209903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Affiliation(s)
- Anouk van Berkel
- Radboudumc, afd. Interne Geneeskunde, Nijmegen
- Contact: A. van Berkel
| | | | | | | | - H G Ruhé
- Radboudumc, afd. Psychiatrie, Nijmegen
| | - C Kramers
- Radboudumc, afd. Interne Geneeskunde, Nijmegen
| |
Collapse
|
9
|
Preeti S, Jayaram SD, Chittaranjan A. Sexual Dysfunction in Patients with Antidepressant-treated Anxiety or Depressive Disorders: a Pragmatic Multivariable Longitudinal Study. East Asian Arch Psychiatry 2018; 28:9-16. [PMID: 29588433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
OBJECTIVE To investigate early evolution, tolerability, and predictors of antidepressant-emergent sexual dysfunction in patients with anxiety or depressive disorder. METHODS Patients with anxiety or depressive disorders who were prescribed antidepressant monotherapy (mirtazapine, sertraline, desvenlafaxine, escitalopram, or fluoxetine) at the discretion of the treating clinician were recruited from July 2012 to June 2014 from a hospital outpatient service. All were free of psychotropic medication for least 1 month. Sexual function was assessed at baseline, week 2, and week 6 using the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ). A PRSexDQ score of ≥2 was considered to indicate sexual dysfunction. Sexual function was dichotomised to 'favourable' or 'impaired'. RESULTS Of 230 patients recruited, 209 were assessed at baseline of whom 184 were assessed at week 2; of these, 154 were also assessed at week 6. At baseline, 138 (66%) of the 209 patients were diagnosed with depressive disorder and 71 (34%) with anxiety disorder; 29% of patients had sexual dysfunction (in any domain of PRSexDQ). By week 6, the percentage had increased to 41%, although the change in the mean PRSexDQ score was only marginal (from 1.04 at baseline to 1.55 at week 6). With regard to individual questionnaire items, by week 6, sexual desire improved, but erectile and ejaculatory function in men and orgasmic function in women worsened. Fluoxetine and sertraline were associated with impaired sexual function, whereas mirtazapine was associated with favourable sexual function. In a logistic regression analysis, at week 2, mirtazapine and desvenlafaxine were predictors of favourable sexual outcome, whereas fluoxetine and higher baseline PRSexDQ score were predictors of impaired sexual outcome. At week 6, mirtazapine remained a predictor of favourable sexual outcome, whereas fluoxetine, higher 2-week PRSexDQ score, and adequate dose were predictors of impaired sexual outcome. CONCLUSIONS In patients with anxiety or depressive disorder, the risk of antidepressant-emergent sexual dysfunction at 6 weeks is low when drug doses are initially low with gradual up-titration. Baseline sexual dysfunction was independently associated with impaired sexual outcome. Men may be more likely than women to experience impaired sexual outcome. In patients with baseline sexual dysfunction, prescription of mirtazapine might be preferable to fluoxetine.
Collapse
Affiliation(s)
- S Preeti
- Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
| | - S D Jayaram
- Department of Pharmacology, Kasturba Medical College, Manipal, Karnataka, India
| | - A Chittaranjan
- Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
| |
Collapse
|
10
|
Morotti E, Casadio P, Guasina F, Battaglia B, Mattioli M, Battaglia C. Weight gain, body image and sexual function in young patients treated with contraceptive vaginal ring. A prospective pilot study. Gynecol Endocrinol 2017; 33:660-664. [PMID: 28412867 DOI: 10.1080/09513590.2017.1306850] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
INTRODUCTION Oral contraceptives could induce mood changes. As far as our knowledge, there are no studies in literature that have examined the role of vaginal contraception in self-perceived body image. AIM To evaluate the effects of intravaginal contraception on weight gain and perceived body image in relation with the Beck's Depression Inventory questionnaire (BDI) and the McCoy Female Sexuality Questionnaire (MFSQ). METHODS Twenty-one adult (18-35 years old) eumenorrheic (menstrual cycle of 25-35 days), lean (body mass index - BMI - of 19-25 kg/m2) women who were referred for hormonal contraception were administered the Stunkard Figure Rating Scale (FRS), BDI and MFSQ. Subjects were studied in basal condition and after 6 months of therapy with vaginal contraception (NuvaRing®; Organon-Schering-Plough Italia, Milan, Italy). MAIN OUTCOME MEASURES BMI, FRS, MFSQ and BDI. RESULTS After 6 months of therapy with NuvaRing®, both body weight (60.0 ± 8.3; p = 0.050) and BMI (22.1 ± 3.1; p = 0.028) slightly, but statistically, increased. FRS and BDI showed no differences after the vaginal contraception. Hormonal contraception was associated with a significant decrease in the two-factor Italian MFSQ score. CONCLUSIONS Vaginal ring seems a good alternative to other hormonal contraceptive not significantly altering the female sexuality and not influencing the FRS and BDI.
Collapse
MESH Headings
- Adolescent
- Adult
- Body Dysmorphic Disorders/chemically induced
- Body Dysmorphic Disorders/ethnology
- Body Dysmorphic Disorders/etiology
- Body Dysmorphic Disorders/psychology
- Body Mass Index
- Contraceptive Devices, Female/adverse effects
- Desogestrel/adverse effects
- Desogestrel/analogs & derivatives
- Drug Combinations
- Ethinyl Estradiol/adverse effects
- Female
- Health Knowledge, Attitudes, Practice/ethnology
- Humans
- Italy
- Overweight/chemically induced
- Overweight/ethnology
- Overweight/etiology
- Overweight/psychology
- Pilot Projects
- Prospective Studies
- Psychiatric Status Rating Scales
- Sexual Dysfunction, Physiological/chemically induced
- Sexual Dysfunction, Physiological/ethnology
- Sexual Dysfunction, Physiological/etiology
- Sexual Dysfunction, Physiological/psychology
- Sexual Dysfunctions, Psychological/chemically induced
- Sexual Dysfunctions, Psychological/ethnology
- Sexual Dysfunctions, Psychological/etiology
- Sexual Dysfunctions, Psychological/psychology
- Weight Gain/drug effects
- Weight Gain/ethnology
- Young Adult
Collapse
Affiliation(s)
- Elena Morotti
- a Department of Gynaecology and Pathophysiology of Human Reproduction , Alma Mater Studiorum-University of Bologna , Italy
| | - Paolo Casadio
- a Department of Gynaecology and Pathophysiology of Human Reproduction , Alma Mater Studiorum-University of Bologna , Italy
| | - Francesca Guasina
- a Department of Gynaecology and Pathophysiology of Human Reproduction , Alma Mater Studiorum-University of Bologna , Italy
| | - Bruno Battaglia
- a Department of Gynaecology and Pathophysiology of Human Reproduction , Alma Mater Studiorum-University of Bologna , Italy
| | - Mara Mattioli
- a Department of Gynaecology and Pathophysiology of Human Reproduction , Alma Mater Studiorum-University of Bologna , Italy
| | - Cesare Battaglia
- a Department of Gynaecology and Pathophysiology of Human Reproduction , Alma Mater Studiorum-University of Bologna , Italy
| |
Collapse
|
11
|
Basaria S, Jasuja R, Huang G, Wharton W, Pan H, Pencina K, Li Z, Travison TG, Bhawan J, Gonthier R, Labrie F, Dury AY, Serra C, Papazian A, O'Leary M, Amr S, Storer TW, Stern E, Bhasin S. Characteristics of Men Who Report Persistent Sexual Symptoms After Finasteride Use for Hair Loss. J Clin Endocrinol Metab 2016; 101:4669-4680. [PMID: 27662439 PMCID: PMC5155688 DOI: 10.1210/jc.2016-2726] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
CONTEXT Some men who use finasteride for hair loss report persistent sexual and other symptoms after discontinuing finasteride therapy. OBJECTIVE To determine whether these persistent symptoms after discontinuation of finasteride use are due to androgen deficiency, decreased peripheral androgen action, or persistent inhibition of steroid 5α-reductase (SRD5A) enzymes. PARTICIPANTS Finasteride users, who reported persistent sexual symptoms after discontinuing finasteride (group 1); age-matched finasteride users who did not report sexual symptoms (group 2); and healthy men who had never used finasteride (group 3). OUTCOMES Sexual function, mood, affect, cognition, hormone levels, body composition, functional magnetic resonance imaging (fMRI) response to sexually and affectively valenced stimuli, nucleotide sequences of androgen receptor (AR), SRD5A1, and SRD5A2; expression levels of androgen-dependent genes in skin. SETTING Academic medical center. RESULTS Symptomatic finasteride users were similar in body composition, strength, and nucleotide sequences of AR, SRD5A1, and SRD5A2 genes to asymptomatic finasteride users and nonusers. Symptomatic finasteride users had impaired sexual function, higher depression scores, a more negative affectivity balance, and more cognitive complaints than men in groups 2 and 3 but had normal objectively assessed cognitive function. Testosterone, dihydrotestosterone, 5α-androstane-3α,17β-diol-glucuronide, testosterone to dihydrotestosterone and androsterone glucuronide to etiocholanolone glucuronide ratios, and markers of peripheral androgen action and expression levels of AR-dependent genes in skin did not differ among groups. fMRI blood oxygen level-dependent responses to erotic and nonerotic stimuli revealed abnormal function in brain circuitry linked to sexual arousal and major depression. CONCLUSIONS We found no evidence of androgen deficiency, decreased peripheral androgen action, or persistent peripheral inhibition of SRD5A in men with persistent sexual symptoms after finasteride use. Symptomatic finasteride users revealed depressed mood and fMRI findings consistent with those observed in depression.
Collapse
MESH Headings
- 5-alpha Reductase Inhibitors/adverse effects
- Adult
- Alopecia/drug therapy
- Androgens/blood
- Depressive Disorder, Major/blood
- Depressive Disorder, Major/chemically induced
- Depressive Disorder, Major/physiopathology
- Finasteride/adverse effects
- Gene Expression
- Humans
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Receptors, Androgen/metabolism
- Sexual Dysfunction, Physiological/blood
- Sexual Dysfunction, Physiological/chemically induced
- Sexual Dysfunction, Physiological/physiopathology
- Sexual Dysfunctions, Psychological/blood
- Sexual Dysfunctions, Psychological/chemically induced
- Sexual Dysfunctions, Psychological/physiopathology
- Young Adult
Collapse
|
12
|
Zethraeus N, Dreber A, Ranehill E, Blomberg L, Labrie F, von Schoultz B, Johannesson M, Hirschberg AL. Combined Oral Contraceptives and Sexual Function in Women-a Double-Blind, Randomized, Placebo-Controlled Trial. J Clin Endocrinol Metab 2016; 101:4046-4053. [PMID: 27525531 DOI: 10.1210/jc.2016-2032] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
CONTEXT There is a lack of knowledge about how oral contraceptives may affect sexual function. OBJECTIVE To determine whether there is a causal effect of oral contraceptives on sexuality. We hypothesized that a widely used pill impairs sexuality. DESIGN A double-blind, randomized, placebo-controlled trial. Enrollment began in February 2012 and was completed in August 2015. SETTING Karolinska University Hospital, Stockholm, Sweden. PARTICIPANTS A total of 340 healthy women, aged 18-35 years, were randomized to treatment, and 332 completed the study. INTERVENTIONS A combined oral contraceptive (150 μg levonorgestrel and 30 μg ethinylestradiol) or placebo for 3 months of treatment. MAIN OUTCOME MEASURES The primary outcome was the aggregate score on the Profile of Female Sexual Function (PFSF). Secondary outcomes were the seven domains of the PFSF, the Sexual Activity Log, and the Personal Distress Scale. RESULTS Overall sexual function was similar in women in the oral contraceptive and placebo groups. The PFSF domains desire (-4.4; 95% confidence interval [CI], -8.49 to -0.38; P = .032), arousal (-5.1; 95% CI, -9.63 to -0.48; P = .030), and pleasure (-5.1; 95% CI, -9.97 to -0.32; P = .036) were significantly reduced in comparison to placebo, whereas orgasm, concern, responsiveness, and self-image were similar between groups. The mean frequency of satisfying sexual episodes and personal distress were also similar between groups. CONCLUSIONS This study shows no negative impact of a levonorgestrel-containing oral contraceptive on overall sexual function, although three of seven sexual function domains were adversely affected.
Collapse
Affiliation(s)
- Niklas Zethraeus
- Department of Learning, Informatics, Management and Ethics (N.Z.), Karolinska Institutet, 171 77 Stockholm, Sweden; Department of Economics (A.D., M.J.), Stockholm School of Economics, 113 83 Stockholm, Sweden; Department of Economics (E.R.), University of Zurich, 8006 Zurich, Switzerland; Department of Women's and Children's Health (L.B., B.v.S., A.L.H), Karolinska Institutet, and Department of Obstetrics and Gynecology, Karolinska University Hospital, 171 76 Stockholm, Sweden; and Laval University (F.L.), Quebec City G1V 0A6, Canada
| | - Anna Dreber
- Department of Learning, Informatics, Management and Ethics (N.Z.), Karolinska Institutet, 171 77 Stockholm, Sweden; Department of Economics (A.D., M.J.), Stockholm School of Economics, 113 83 Stockholm, Sweden; Department of Economics (E.R.), University of Zurich, 8006 Zurich, Switzerland; Department of Women's and Children's Health (L.B., B.v.S., A.L.H), Karolinska Institutet, and Department of Obstetrics and Gynecology, Karolinska University Hospital, 171 76 Stockholm, Sweden; and Laval University (F.L.), Quebec City G1V 0A6, Canada
| | - Eva Ranehill
- Department of Learning, Informatics, Management and Ethics (N.Z.), Karolinska Institutet, 171 77 Stockholm, Sweden; Department of Economics (A.D., M.J.), Stockholm School of Economics, 113 83 Stockholm, Sweden; Department of Economics (E.R.), University of Zurich, 8006 Zurich, Switzerland; Department of Women's and Children's Health (L.B., B.v.S., A.L.H), Karolinska Institutet, and Department of Obstetrics and Gynecology, Karolinska University Hospital, 171 76 Stockholm, Sweden; and Laval University (F.L.), Quebec City G1V 0A6, Canada
| | - Liselott Blomberg
- Department of Learning, Informatics, Management and Ethics (N.Z.), Karolinska Institutet, 171 77 Stockholm, Sweden; Department of Economics (A.D., M.J.), Stockholm School of Economics, 113 83 Stockholm, Sweden; Department of Economics (E.R.), University of Zurich, 8006 Zurich, Switzerland; Department of Women's and Children's Health (L.B., B.v.S., A.L.H), Karolinska Institutet, and Department of Obstetrics and Gynecology, Karolinska University Hospital, 171 76 Stockholm, Sweden; and Laval University (F.L.), Quebec City G1V 0A6, Canada
| | - Fernand Labrie
- Department of Learning, Informatics, Management and Ethics (N.Z.), Karolinska Institutet, 171 77 Stockholm, Sweden; Department of Economics (A.D., M.J.), Stockholm School of Economics, 113 83 Stockholm, Sweden; Department of Economics (E.R.), University of Zurich, 8006 Zurich, Switzerland; Department of Women's and Children's Health (L.B., B.v.S., A.L.H), Karolinska Institutet, and Department of Obstetrics and Gynecology, Karolinska University Hospital, 171 76 Stockholm, Sweden; and Laval University (F.L.), Quebec City G1V 0A6, Canada
| | - Bo von Schoultz
- Department of Learning, Informatics, Management and Ethics (N.Z.), Karolinska Institutet, 171 77 Stockholm, Sweden; Department of Economics (A.D., M.J.), Stockholm School of Economics, 113 83 Stockholm, Sweden; Department of Economics (E.R.), University of Zurich, 8006 Zurich, Switzerland; Department of Women's and Children's Health (L.B., B.v.S., A.L.H), Karolinska Institutet, and Department of Obstetrics and Gynecology, Karolinska University Hospital, 171 76 Stockholm, Sweden; and Laval University (F.L.), Quebec City G1V 0A6, Canada
| | - Magnus Johannesson
- Department of Learning, Informatics, Management and Ethics (N.Z.), Karolinska Institutet, 171 77 Stockholm, Sweden; Department of Economics (A.D., M.J.), Stockholm School of Economics, 113 83 Stockholm, Sweden; Department of Economics (E.R.), University of Zurich, 8006 Zurich, Switzerland; Department of Women's and Children's Health (L.B., B.v.S., A.L.H), Karolinska Institutet, and Department of Obstetrics and Gynecology, Karolinska University Hospital, 171 76 Stockholm, Sweden; and Laval University (F.L.), Quebec City G1V 0A6, Canada
| | - Angelica Lindén Hirschberg
- Department of Learning, Informatics, Management and Ethics (N.Z.), Karolinska Institutet, 171 77 Stockholm, Sweden; Department of Economics (A.D., M.J.), Stockholm School of Economics, 113 83 Stockholm, Sweden; Department of Economics (E.R.), University of Zurich, 8006 Zurich, Switzerland; Department of Women's and Children's Health (L.B., B.v.S., A.L.H), Karolinska Institutet, and Department of Obstetrics and Gynecology, Karolinska University Hospital, 171 76 Stockholm, Sweden; and Laval University (F.L.), Quebec City G1V 0A6, Canada
| |
Collapse
|
13
|
Finasteride 1 mg in alopecia: sexual dysfunction, suicidal ideation. Providing balanced information to male patients is key. Prescrire Int 2016; 25:242. [PMID: 30688421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
|
14
|
Abstract
OBJECTIVE: To review the evidence regarding antidepressant-induced sexual dysfunction and address implications for treatment strategy and health plan coverage policies for antidepressant medications. DATA SOURCES: Primary articles were identified by a MEDLINE and HealthSTAR search to identify English-language studies published between January 1986 and July 2000. Search terms included sexual dysfunction or sexual function and antidepressants, fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram, venlafaxine, nefazodone, bupropion, and mirtazapine. A cross-check of references cited in 10 published reviews yielded additional in-scope articles. STUDY SELECTION AND DATA EXTRACTION: Approximately 200 articles were identified, including 8 randomized controlled trials and numerous open-label studies, case series, and case reports. Of the randomized controlled trials, only 5 were designed to evaluate the incidence of sexual dysfunction associated with antidepressant treatment. Three additional randomized controlled trials included a structured assessment of sexual dysfunction within an efficacy trial. Data extraction excluded case reports, letters, and other limited study designs. A panel survey augmented published reports. DATA SYNTHESIS: Sexual dysfunction is a relatively common adverse effect of many of the antidepressants in common use today. Rates of sexual dysfunction observed in clinical practice may be higher than those reported in the product information for several agents. Selective serotonin-reuptake inhibitors (SSRIs) appear to be the class of antidepressants most likely to cause sexual dysfunction. Published studies suggest that between 30% and 60% of SSRI-treated patients may experience some form of treatment-induced sexual dysfunction. Bupropion and nefazodone appear to be much less likely to cause sexual dysfunction (≤10% of patients). Mirtazapine also appears to be associated with a low rate of sexual adverse effects. Panel results largely reflect the consensus of the literature. CONCLUSIONS: Sexual dysfunction is a common adverse effect of antidepressant treatment. Physicians should monitor their patients for antidepressant-induced sexual adverse effects, as these may affect compliance with therapy and ultimate treatment success. In addition to the consequences for patient health and well-being, managed-care organizations should be concerned with sexually related adverse effects of antidepressants, insofar as additional healthcare resources may be required to treat depressed patients in whom these adverse effects arise.
Collapse
|
15
|
Abstract
OBJECTIVE To examine the effect of hormonal contraception on sexual desire. MATERIALS AND METHODS We performed a cross-sectional analysis of 1,938 of the 9,256 participants enrolled in the Contraceptive CHOICE Project. This subset included participants enrolled between April and September 2011 who completed a baseline and 6-month telephone survey. Multivariable logistic regression was used to assess the association between contraceptive method and report of lacking interest in sex controlling for potential confounding variables. RESULTS More than 1 in 5 participants (23.9%) reported lacking interest in sex at 6 months after initiating a new contraceptive method. Of 262 copper intrauterine device (IUD) users (referent group), 18.3% reported lacking interest in sex. Our primary outcome was more prevalent in women who were young (younger than 18 years: adjusted odds ratio [OR] 2.04), black (adjusted OR 1.78), and married or living with a partner (adjusted OR 1.82). Compared with copper IUD users, participants using depot medroxyprogesterone (adjusted OR 2.61, 95% confidence interval [CI] 1.47-4.61), the vaginal ring (adjusted OR 2.53, 95% CI 1.37-4.69), and the implant (adjusted OR 1.60, 95% CI 1.03-2.49) more commonly reported lack of interest in sex. We found no association between use of the hormonal IUD, oral contraceptive pill, and patch and lack of interest in sex. CONCLUSION CHOICE participants using depot medroxyprogesterone acetate, the contraceptive ring, and implant were more likely to report a lack of interest in sex compared with copper IUD users. Future research should confirm these findings and their possible physiologic basis. Clinicians should be reassured that most women do not experience a reduced sex drive with the use of most contraceptive methods.
Collapse
Affiliation(s)
- Amanda Boozalis
- Division of Clinical Research, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri
| | | | | | | |
Collapse
|
16
|
Genek Ülgen M, Güleç G. Evaluation of Changes in Anxiety and Depression Symptoms, and Sexual Functions in Patients Receiving Antidepressants: 3 Months-Long Naturalistic Follow-Up Study. Turk Psikiyatri Derg 2016; 27:161-169. [PMID: 27711936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
OBJECTIVE The aim of this study was to study the change in sexual functions within 3 months period following the initiation of antidepressant treatment in psychiatry outpatients, and its relationship with the change in anxiety and depression symptoms. MATERIAL AND METHOD Eighty two patients, who consecutively applied to the psychiatry outpatient clinic and who were prescribed antidepressants, were included in the study. Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, General Assessment of Functioning Scale and Arizona Sexual Experience Questionnaire (ASEC) were administered to the patients at the first interview, then repeated on a monthly basis during 3 months. RESULTS Fifty seven of the patients (69.50 %) has been diagnosed with sexual dysfunctions prior to the antidepressant treatment. During the third month after the antidepressant treatment, 24 patients in this group (42.11%) showed no impairment in ASEC scores, whereas 33 patients' (57.89%) scores were still at impairment level. Eight patients out of 25 (32%) who weren't diagnosed with sexual dysfunctions prior to the treatment were later diagnosed with sexual dysfunctions. Sexual dysfunctions correlated with patients' level of functioning, separately from anxiety and depression symptoms. RESULTS Our study results show that the sexual dysfunction rate is quite high in psychiatric patients population. However, sexual dysfunctions rate which can be related to antidepressant treatment is 36%. It would be appropriate for clinicians to determine benefit-loss balance by considering patients' mental syndromes together with sexual functions.
Collapse
|
17
|
|
18
|
Caruso D, Abbiati F, Giatti S, Romano S, Fusco L, Cavaletti G, Melcangi RC. Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. J Steroid Biochem Mol Biol 2015; 146:74-9. [PMID: 24717976 DOI: 10.1016/j.jsbmb.2014.03.012] [Citation(s) in RCA: 57] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2014] [Revised: 03/28/2014] [Accepted: 03/31/2014] [Indexed: 11/16/2022]
Abstract
Observations performed in a subset of patients treated for male pattern hair loss indicate that persistent sexual side effects as well as anxious/depressive symptomatology have been reported even after discontinuation of finasteride treatment. Due to the capability of finasteride to block the metabolism of progesterone (PROG) and/or testosterone (T) we have evaluated, by liquid chromatography-tandem mass spectrometry, the levels of several neuroactive steroids in paired plasma and cerebrospinal fluid (CSF) samples obtained from post-finasteride patients and in healthy controls. At the examination, post-finasteride patients reported muscular stiffness, cramps, tremors and chronic fatigue in the absence of clinical evidence of any muscular disorder or strength reduction. Although severity of the anxious/depressive symptoms was quite variable in their frequency, overall all the subjects had a fairly complex and constant neuropsychiatric pattern. Assessment of neuroactive steroid levels in CSF showed a decrease of PROG and its metabolites, dihydroprogesterone (DHP) and tetrahydroprogesterone (THP), associated with an increase of its precursor pregnenolone (PREG). Altered levels were also observed for T and its metabolites. Thus, a significant decrease of dihydrotestosterone (DHT) associated with an increase of T as well as of 3α-diol was detected. Changes in neuroactive steroid levels also occurred in plasma. An increase of PREG, T, 3α-diol, 3β-diol and 17β-estradiol was associated with decreased levels of DHP and THP. The present observations show that altered levels of neuroactive steroids, associated with depression symptoms, are present in androgenic alopecia patients even after discontinuation of the finasteride treatment. This article is part of a Special Issue entitled 'Sex steroids and brain disorders'.
Collapse
Affiliation(s)
- Donatella Caruso
- Department of Pharmacological and Biomolecular Sciences - Center of Excellence on Neurodegenerative Diseases, Università degli Studi di Milano, Milano, Italy
| | - Federico Abbiati
- Department of Pharmacological and Biomolecular Sciences - Center of Excellence on Neurodegenerative Diseases, Università degli Studi di Milano, Milano, Italy
| | - Silvia Giatti
- Department of Pharmacological and Biomolecular Sciences - Center of Excellence on Neurodegenerative Diseases, Università degli Studi di Milano, Milano, Italy
| | - Simone Romano
- Department of Pharmacological and Biomolecular Sciences - Center of Excellence on Neurodegenerative Diseases, Università degli Studi di Milano, Milano, Italy
| | - Letizia Fusco
- Department of Surgery and Translational Medicine, University of Milan-Bicocca, Monza, Italy; Department of Neurology, S. Gerardo Hospital, Monza, Italy
| | - Guido Cavaletti
- Department of Surgery and Translational Medicine, University of Milan-Bicocca, Monza, Italy; Department of Neurology, S. Gerardo Hospital, Monza, Italy
| | - Roberto Cosimo Melcangi
- Department of Pharmacological and Biomolecular Sciences - Center of Excellence on Neurodegenerative Diseases, Università degli Studi di Milano, Milano, Italy.
| |
Collapse
|
19
|
Clark MS, Jansen K, Bresnahan M. Clinical inquiry: How do antidepressants affect sexual function? J Fam Pract 2013; 62:660-661. [PMID: 24288712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Affiliation(s)
- Molly S Clark
- University of Mississippi Medical Center, Jackson, MS, USA
| | | | | |
Collapse
|
20
|
Reyes D, Kurako K, Galvez-Jimenez N. Rasagiline induced hypersexuality in Parkinson's disease. J Clin Neurosci 2013; 21:507-8. [PMID: 24055209 DOI: 10.1016/j.jocn.2013.04.021] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2012] [Revised: 04/04/2013] [Accepted: 04/07/2013] [Indexed: 11/19/2022]
Abstract
Impulse control disorders (ICD) are increasingly recognized in patients with Parkinson's disease (PD), particularly when treated with commonly used dopamine agonists such as pramipexole and ropinirole. Less evident is the possible association between monoamine oxidase inhibitors type B (MAO-B) and the development of ICD. Rasagiline is a second generation MAO-B I inducing moderate symptomatic and possibly disease modifying benefits with apparently good tolerability and safety profile in PD patients. Rasagiline is effective and well tolerated in PD as a monotherapy or in combination with levodopa. Here, we report a patient with PD who developed ICD when treated de novo with MAO-B inhibitors.
Collapse
Affiliation(s)
- Dennys Reyes
- Department of Neurology, Cleveland Clinic Florida, 2950 Cleveland Clinic Boulevard, Weston, FL 33331, USA
| | - Kateryna Kurako
- Department of Neurology, Cleveland Clinic Florida, 2950 Cleveland Clinic Boulevard, Weston, FL 33331, USA.
| | - Nestor Galvez-Jimenez
- Department of Neurology, Cleveland Clinic Florida, 2950 Cleveland Clinic Boulevard, Weston, FL 33331, USA
| |
Collapse
|
21
|
Affiliation(s)
- Sakina J Rizvi
- Departments of Pharmaceutical Sciences and Neuroscience, University of Toronto, Department of Psychiatry, University Health Network, Toronto, Ont., Canada
| | | |
Collapse
|
22
|
Metzger CD, Walter M, Graf H, Abler B. SSRI-related modulation of sexual functioning is predicted by pre-treatment resting state functional connectivity in healthy men. Arch Sex Behav 2013; 42:935-947. [PMID: 23771550 DOI: 10.1007/s10508-013-0103-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/03/2012] [Revised: 11/20/2012] [Accepted: 12/21/2012] [Indexed: 06/02/2023]
Abstract
Sexual dysfunction related to treatment with selective serotonin reuptake inhibitors (SSRIs) is a common reason for discontinuation of otherwise effective antidepressant treatment regimens. Thus, identification of subjects at risk for this side effect remains a crucial challenge. After demonstrating task-related neural correlates of impaired sexual functioning under treatment with the SSRI paroxetine (Abler et al., 2011), we studied (1) if resting state brain function before treatment predicts subsequent development of treatment-related modulation of sexual function, and (2) which neural circuits relate to different aspects of the impairment. Effects of paroxetine and bupropion administration over 1 week on subjective sexual functioning were investigated in 17 healthy male volunteers in a placebo-controlled, randomized cross-over design using the Massachusetts General Hospital Sexual Function Questionnaire. Data from a 10 min eyes-closed resting state scan were used to analyze functional connectivity under placebo in previously identified brain regions, focussing on the sublenticular extended amygdala (SLEA), dopaminergic midbrain, and anterior cingulate cortex. Resting state functional connectivities of the pregenual anterior cingulate cortex (pgACC), midbrain, and insula to the SLEA sufficiently predicted the development of subjective SSRI-related decreased sexual functioning and distinguished vulnerable from resilient subjects. Furthermore, connectivity with the midbrain particularly predicted orgasm-related deficits, while connectivity with pgACC predicted sexual satisfaction. Linking SSRI-related subjective sexual functioning to pre-treatment resting state connectivities in cortico-subcortical network of sexual processing, we demonstrated the potential of novel, non-invasive and passive brain imaging techniques to guide therapeutic decisions and adjust treatment protocols in psychiatric disorders and sexual medicine.
Collapse
Affiliation(s)
- Coraline D Metzger
- Department of Psychiatry and Psychotherapy, Centre for Behavioral Brain Sciences, Otto-von-Guericke University, Magdeburg, Germany
| | | | | | | |
Collapse
|
23
|
|
24
|
Abstract
Paroxetine-induced sexual dysfunction represents a frequent treatment complication of otherwise efficient antidepressants. The genetic polymorphism of pharmacokinetic genes may contribute to the occurrence of such dysfunctions. This study presents the effect of MDR1 gene polymorphisms on sexual function in 18 women with bulimia nervosa, 18 women with anxiety disorders, and 19 healthy control subjects. It also deals with the relation between MDR1 gene polymorphisms and paroxetine-induced sexual dysfunction. The results demonstrated that MDR1 G2677T/A gene polymorphism allele carriers treated with paroxetine presented with difficulties with orgasm (p = .008) and lubrication (p < .001).
Collapse
Affiliation(s)
- Alexandra Zourková
- Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
| | | | | | | | | | | |
Collapse
|
25
|
Bishop JR, Chae SS, Patel S, Moline J, Ellingrod VL. Pharmacogenetics of glutamate system genes and SSRI-associated sexual dysfunction. Psychiatry Res 2012; 199:74-6. [PMID: 22534499 PMCID: PMC3458139 DOI: 10.1016/j.psychres.2012.03.048] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/10/2011] [Revised: 03/12/2012] [Accepted: 03/25/2012] [Indexed: 10/28/2022]
Abstract
We examined whether polymorphisms in the GRIK2, GRIA3 and GRIA1 genes were associated with selective serotonin reuptake inhibitor (SSRI)-associated sexual dysfunction in 114 participants treated for depression. One polymorphism in GRIA1 (rs1994862) was associated with arousal dysfunction, providing further evidence for the role of GRIA1 in mechanisms underlying SSRI-associated sexual side effects.
Collapse
Affiliation(s)
- Jeffrey R Bishop
- University of Illinois at Chicago College of Pharmacy, Department of Pharmacy Practice, Chicago, IL, USA.
| | | | | | | | | |
Collapse
|
26
|
Lara LADS, Duarte AAF, Reis RM, Vieira CS, Rosa-e-Silva ACJDS. Endocrine disrupters: potential risk factors affecting sexual function in both men and women. J Sex Med 2012; 9:941-2. [PMID: 22239867 DOI: 10.1111/j.1743-6109.2011.02596.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
27
|
Abstract
Sexual dysfunctions caused by the use of antidepressants are relatively common. Agomelatine has demonstrated antidepressant properties in comparative studies with sertraline, fluoxetine, and venlafaxine as active controls. The aim of this study was to evaluate the effects of agomelatine on sexual response. Acutely depressed patients (n = 25) treated with agomelatine (25-50 mg/day) were evaluated over 12 weeks. Agomelatine showed a favorable response on depressive symptoms using the Montgomery-Åsberg Depression Rating Scale throughout the study. The Clinical Global Impression improvement score at the end of the study was 1.70 (SD = 0.89). The author assessed sexual response using the Arizona Sexual Experiences Scale, the International Index of Erectile Function, and a Visual Analogue Scale for desire, arousal, time, and intensity of orgasm and vaginal lubrication. Arizona Sexual Experiences Scale scores improved after 3 weeks of treatment, mainly attributable to an improvement in women rather than in men. The Visual Analogue Scale showed improvement in all stages of sexual response in women, with minimal changes in men. Clinical Satisfaction Scores at the end of the study for all patients were 7.00 (SD = 1.53). In conclusion, agomelatine appears to be a good option for the treatment of depression because it would not have adverse effects on sexual function.
Collapse
Affiliation(s)
- Adrian Sapetti
- Centro Medico Sexologico, Capital Federal, Buenos Aires, Argentina.
| |
Collapse
|
28
|
Gałecki P, Depko A, Woźniak A, Talarowska M. [Depressive disorder, treatment and sexual dysfunction--part II]. Pol Merkur Lekarski 2011; 31:256-259. [PMID: 22097187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Depressive disorders and antidepressant therapy have been associated with sexual dysfunction. Sexual dysfunctions are recognized as a potential side effect of antidepressant therapy. Not reliable algorithms have been developed in the presence of sexual dysfunctions in the course of depressive disorders. The most commonly used methods of treatment of sexual dysfunction in depressive disorders include: waiting for spontaneous remission, reduction in dose of a repressive drug, the change of drug discontinuation for a short time, the use of the drug after having sexual intercourse, drug holidays and corrective medications (yohimbine, phosphodiesterase type 5 and anesthetic creams). Among the most effective agents used in the treatment sre: bupropion, trazodone, nefazodone, agomelatine, tianeptine and flibanserin. Optimal antidepressant treatment should result in remission of the symptoms of the underlying illness and minimize the potential for short-term and long-term adverse effects, including sexual dysfunction. Physicians should monitor their patients for antidepressant-induced sexual adverse effects, as these may affect compliance with therapy and ultimate treatment success.
Collapse
Affiliation(s)
- Piotr Gałecki
- Uniwersytet Medyczny w Łodzi, Klinika Psychiatrii Dorosłych
| | | | | | | |
Collapse
|
29
|
Abstract
Hyperprolactinaemia is a common side effect in people receiving antipsychotics. The propensity to cause hyperprolactinaemia differs markedly between antipsychotics as a result of differential dopamine D(2) receptor-binding affinity and ability to cross the blood-brain barrier. Sexual dysfunction is common and under-recognized in people with severe mental illness and is in part caused by hyperprolactinaemia. There are a number of long-term consequences of hyperprolactinaemia, including osteoporosis. Regular monitoring before and during treatment will help identify those developing antipsychotic-induced hyperprolactinaemia. The treatment includes dose reduction and change in antipsychotic. Where this is not possible because of the risk of relapse of the mental illness, sex steroid replacement may be helpful in improving symptoms secondary to hypogonadism and reducing the risk of osteoporosis. Tertiary prevention of complications should also be considered.
Collapse
Affiliation(s)
- Richard I G Holt
- Endocrinology and Metabolism Sub-Division, Developmental Origins of Adult Health and Disease Division, University of Southampton School of Medicine, Southampton, UK.
| | | |
Collapse
|
30
|
Iagubov MI, Shtark LN. [Sexual disturbances during the treatment with neuroleptics in patients with schizophrenia and schizophrenia spectrum disorders]. Zh Nevrol Psikhiatr Im S S Korsakova 2011; 111:57-60. [PMID: 22027609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Sixty male patients with schizophrenia and schizophrenia spectrum disorders were studied in the first five years of disease. Characteristics of psychosexual development and sexual behavior were reviewed. Sexual disorders (mostly the decreased libido) developed in patients during the worsening of mental state and were aggravated during the treatment with neuroleptics. The disturbances of ejaculation appeared during the treatment with risperidone and olanzapine but not with quetiapine. Peculiarities of structure and dynamics of sexual disorders in patients were revealed.
Collapse
|
31
|
Abstract
The selective serotonin reuptake inhibitor (SSRI), fluoxetine (Prozac(R)), is an effective antidepressant that is also prescribed for other disorders (e.g. anorexia, bulimia, and premenstrual dysphoria) that are prevalent in females. However, fluoxetine also produces sexual side effects that may lead patients to discontinue treatment. The current studies were designed to evaluate several predictions arising from the hypothesis that serotonin 1A (5-HT(1A)) receptors contribute to fluoxetine-induced sexual dysfunction. In rodent models, 5-HT(1A) receptors are potent negative modulators of female rat sexual behavior. Three distinct experiments were designed to evaluate the contribution of 5-HT(1A) receptors to the effects of fluoxetine. In the first experiment, the ability of the 5-HT(1A) receptor antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide (WAY100635), to prevent fluoxetine-induced lordosis inhibition was examined. In the second experiment, the effects of prior treatment with fluoxetine on the lordosis inhibitory effect of the 5-HT(1A) receptor agonist, (+/-)-8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT), were studied. In the third experiment, the ability of progesterone to reduce the acute response to fluoxetine was evaluated. WAY100635 attenuated the effect of fluoxetine; prior treatment with fluoxetine decreased 8-OH-DPAT's potency in reducing lordosis behavior; and progesterone shifted fluoxetine's dose-response curve to the right. These findings are consistent with the hypothesis that 5-HT(1A) receptors contribute to fluoxetine-induced sexual side effects.
Collapse
MESH Headings
- 8-Hydroxy-2-(di-n-propylamino)tetralin/pharmacology
- Animals
- Dose-Response Relationship, Drug
- Female
- Fluoxetine/administration & dosage
- Fluoxetine/adverse effects
- Fluoxetine/pharmacology
- Models, Animal
- Ovariectomy
- Piperazines/pharmacology
- Progesterone/metabolism
- Pyridines/pharmacology
- Rats
- Rats, Inbred F344
- Receptor, Serotonin, 5-HT1A/metabolism
- Serotonin 5-HT1 Receptor Agonists
- Serotonin 5-HT1 Receptor Antagonists
- Serotonin Antagonists/pharmacology
- Serotonin Receptor Agonists/pharmacology
- Selective Serotonin Reuptake Inhibitors/administration & dosage
- Selective Serotonin Reuptake Inhibitors/adverse effects
- Selective Serotonin Reuptake Inhibitors/pharmacology
- Sexual Behavior, Animal/drug effects
- Sexual Behavior, Animal/physiology
- Sexual Dysfunctions, Psychological/chemically induced
- Sexual Dysfunctions, Psychological/drug therapy
- Sexual Dysfunctions, Psychological/metabolism
- Time Factors
Collapse
Affiliation(s)
- Jutatip Guptarak
- Department of Biology, Texas Woman's University, Denton, Texas 76204, USA
| | | | | | | |
Collapse
|
32
|
Odiyoor M, Kobylecki C, Hackett RJ, Silverdale MA, Kellett MW. Pramipexole and gender identity disorder: expanding the phenotype of hypersexuality in Parkinson's disease. Mov Disord 2010; 24:2434-5. [PMID: 19891000 DOI: 10.1002/mds.22848] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
|
33
|
Simões S, Amorim J, Machado A. Intense lorazepam-induced sexual arousal. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:236-7. [PMID: 19786053 DOI: 10.1016/j.pnpbp.2009.09.021] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/16/2009] [Revised: 09/17/2009] [Accepted: 09/17/2009] [Indexed: 11/18/2022]
|
34
|
Abstract
Androgen deprivation therapy (ADT) is being increasingly used to treat men with prostate cancer. ADT has been associated with many side effects that may persist for the lifetime of the patient and can have potentially devastating effects on the quality of life of both men and their intimate relationships. Despite U.S. estimates that more than 40,000 men begin ADT each year and live on average for 10 years, there have been few studies examining the effect of ADT on couples. This article reviews the emerging literature on the challenges faced by men and their partners while undergoing ADT. Loss of libido, erectile dysfunction, genital shrinkage, low self-esteem, and diminished masculinity are commonly associated with undergoing ADT. These losses frequently lead to changes in the marital relationship in areas such as roles and responsibilities, communication, and intimacy. Intervention strategies for helping couples maintain a strong relational bond need to be selected carefully for this population because of these unique and profound changes. Couples who succeed in maintaining sexuality and intimacy have been shown to have higher quality of life and more satisfying relationships.
Collapse
Affiliation(s)
- Lauren M Walker
- Department of Psychology, University of Calgary, Calgary, Alberta, Canada
| | | |
Collapse
|
35
|
Sharpe RM. Bisphenol A exposure and sexual dysfunction in men: editorial commentary on the article 'Occupational exposure to bisphenol-A (BPA) and the risk of self-reported male sexual dysfunction' Li et al., 2009. Hum Reprod 2009; 25:292-4. [PMID: 19906655 DOI: 10.1093/humrep/dep385] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Nappi RE, Albani F, Tonani S, Santamaria V, Pisani C, Terreno E, Martini E, Polatti F. Psychosexual well-being in women using oral contraceptives containing drospirenone. Funct Neurol 2009; 24:71-75. [PMID: 19775533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Considerable advances have been made in hormonal contraception in recent years, geared at maximizing compliance and minimizing discontinuation. In oral contraceptive (OC) formulations, the estrogenic component, generally ethinyl estradiol (EE), has been reduced significantly and newer progestins like dienogest and drospirenone (DRSP), compounds with different molecular structures, have been introduced; in addition, new regimens (extended, flexible, 24/4 formats instead of the standard 21/7 format) and innovative delivery systems (vaginal rings, transdermal patches, subcutaneous implants and intrauterine devices) are available. The multitude of choices allows hormonal contraception to be tailored to the individual woman in order to obtain non-contraceptive benefits, without significant side effects, and also a favorable risk/benefit profile for her general and reproductive health. Over the past few years, new OC formulations combining DRSP (3 mg), a unique progestin with both antimineralocorticoid and antiandrogenic activities, with estrogen (30 mcg or 20 mcg EE), in two regimens (24/4 and 21/7) of active pills in a 28-day cycle, have shown positive effects on water retention-related weight gain and physical, emotional and psychosexual well-being. It seems likely that the use of a low-dose, well-balanced OC and the shorter 4-day hormone-free interval may minimize the side effects that can impair quality of life and thus increase women's compliance with hormonal contraception therapy.
Collapse
Affiliation(s)
- Rossella E Nappi
- Research Center for Reproductive Medicine, Section of Obstetrics and Gynecology, Department of Morphological, Eidological and Clinical Sciences, University of Pavia, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Viagra, sex, and antidepressants. Johns Hopkins Med Lett Health After 50 2009; 21:7. [PMID: 19370801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
|
38
|
Lasaosa SS, Fernández LG, del Val LJL. [Anorgasmia due to topiramate]. Neurologia 2008; 23:541-542. [PMID: 19035003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
|
39
|
Viagra improves sexual function in women taking antidepressants. Harv Womens Health Watch 2008; 16:7. [PMID: 19051427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
|
40
|
Meston CM, Rellini AH, Telch MJ. Short- and long-term effects of Ginkgo biloba extract on sexual dysfunction in women. Arch Sex Behav 2008; 37:530-47. [PMID: 18274887 PMCID: PMC2863090 DOI: 10.1007/s10508-008-9316-2] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/05/2006] [Revised: 09/15/2006] [Accepted: 09/15/2006] [Indexed: 05/25/2023]
Abstract
Ginkgo biloba extract (GBE) facilitates blood flow, influences nitric oxide systems, and has a relaxant effect on smooth muscle tissue. These processes are important to the sexual response in women and, hence, it is feasible that GBE may have a therapeutic effect. The present study was the first to provide an empirical examination of the effects of both short- and long-term GBE administration on subjective and physiological (vaginal photoplethysmography) measures of sexual function in women with Sexual Arousal Disorder. A single dose of 300 mg GBE had a small but significant facilitatory effect on physiological, but not subjective, sexual arousal compared to placebo in 99 sexually dysfunctional women. The long-term effects of GBE on sexual function were assessed in 68 sexually dysfunctional women who were randomly assigned to 8 weeks treatment of either (1) GBE (300 mg/daily), (2) placebo, (3) sex therapy which focused on training women to attend to genital sensations, or (4) sex therapy plus GBE. When combined with sex therapy, but not alone, long-term GBE treatment significantly increased sexual desire and contentment beyond placebo. Sex therapy alone significantly enhanced orgasm function compared with placebo. Long-term GBE administration did not significantly enhance arousal responses beyond placebo. It was concluded that (1) neither short- or long-term administration of GBE alone substantially impacts sexual function in women, (2) a substantial placebo effect on sexual function exists in women with sexual concerns, and (3) teaching women to focus on genital sensations during sex enhances certain aspects of women's sexual functioning.
Collapse
Affiliation(s)
- Cindy M Meston
- Department of Psychology, University of Texas at Austin, One University Station A8000, Austin, TX 78712, USA.
| | | | | |
Collapse
|
41
|
Montejo AL, Rico-Villademoros F. Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders. J Sex Marital Ther 2008; 34:227-239. [PMID: 18398761 DOI: 10.1080/00926230701866125] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Sexual dysfunction is a disturbing and often underrecognized problem associated with schizophrenia and its treatment. The Psychotropic-Related Sexual Dysfunction (PRSexDQ-SALSEX) is a brief and relatively nonintrusive questionnaire that has shown adequate psychometric properties in patients with depression. This study examined the psychometric properties of the PRSexDQ-SALSEX in a sample of patients with schizophrenia or other psychotic disorders who were experiencing anti-psychotic-induced sexual dysfunction and were switched to olanzapine. The PRSexDQ-SALSEX was very feasible and its internal reliability was satisfactory. In addition, this questionnaire showed a good convergent validity and sensitivity to tracking changes in sexual functioning.
Collapse
Affiliation(s)
- Angel L Montejo
- Servicio de Psiquiatría, Hospital Universitario de Salamanca, Salamanca, Spain.
| | | |
Collapse
|
42
|
Konarzewska B, Szulc A, Popławska R, Galińska B, Juchnowicz D. [Impact of neuroleptic-induced hyperprolactinemia on sexual dysfunction in male schizophrenic patients]. Psychiatr Pol 2008; 42:87-95. [PMID: 18567406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Human sexual function is complex and effected in many different ways by schizophrenia and the antipsychotic drugs used in its treatment. Although not extensively researched, sexual dysfunction seems to be frequent in patients with schizophrenia, especially in men. They appear, in significant part, to be a direct consequence of dopamine antagonism, combined with indirect effects due to increased serum prolactin (PRL) concentration. All of the typical antipsychotics and risperidone can cause substantial PRL elevation. Hyperprolactinemia in male schizophrenics might decrease libido, cause anorgasmia and lead to erectile dysfunction. These sexual side effects are closely associated with the patients' willingness to take antipsychotics, and can affect compliance.
Collapse
|
43
|
Baldwin D, Hutchison J, Donaldson K, Shaw B, Smithers A. Selective serotonin re-uptake inhibitor treatment-emergent sexual dysfunction: randomized double-blind placebo-controlled parallel-group fixed-dose study of a potential adjuvant compound, VML-670. J Psychopharmacol 2008; 22:55-63. [PMID: 17715211 DOI: 10.1177/0269881107078490] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Sexual dysfunction is common during acute and continuation treatment of depressed patients with selective serotonin (5-hydroxytryptamine, 5-HT) re-uptake inhibitors (ssRIs), but there is no consensus on clinical management. Compounds with 5-HT(1A) agonist properties have been proposed as adjuvant agents in patients continuing with ssRIs. Randomized double-blind placebo-controlled parallel-group fixed-dose 4-week treatment study. Previously depressed male or female patients in symptomatic remission receiving stable doses of fluoxetine or paroxetine but experiencing treatment-emergent sexual dysfunction were randomised to double-blind treatment with placebo or VML-670 (a 5-HT(1A) and 5-HT(1D) agonist). sexual dysfunction was assessed by the Arizona sexual Experiences scale (ASEX). Two-hundred and eighty-eight patients (204 women, 84 men; mean age 44.2 years) received VML-670 (n = 149; 107 women, 42 men) or placebo (n = 139; 97 women, 42 men). In the intention-to-treat, last-observation carried forward analysis (n = 282), proportionately more patients became free of sexual dysfunction with VML-670 (34.3% versus 27.9% with placebo) but this difference was not statistically significant. Male patients treated with VML-670 showed a significantly greater (p =0.01) improvement in ability to achieve and maintain penile erection (a secondary outcome measure). A similar proportion of patients reported on-treatment, treatment-emergent adverse events with VML-670 (71.1%) and placebo (68.3%), and a similar proportion experienced at least one treatment-related adverse event (36.9% versus 35.3%). Double-blind treatment with VML-670 offered no significant advantage over placebo on the primary outcome measure in the overall sample. Further studies may be warranted in larger groups of male patients with sexual dysfunction.
Collapse
Affiliation(s)
- David Baldwin
- Clinical Neuroscience Division, University of Southampton, Southampton, UK.
| | | | | | | | | |
Collapse
|
44
|
Asboe D, Catalan J, Mandalia S, Dedes N, Florence E, Schrooten W, Noestlinger C, Colebunders R. Sexual dysfunction in HIV-positive men is multi-factorial: a study of prevalence and associated factors. AIDS Care 2007; 19:955-65. [PMID: 17851990 DOI: 10.1080/09540120701209847] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
To establish the prevalence of sexual dysfunction amongst HIV-positive men and to determine the factors associated with dysfunction we conducted a cross-sectional study in seven European HIV treatment centres. Data on medical history, antiretroviral treatment and laboratory results were collected by interview and case record review. Sexual function was evaluated by the participant self-completion of a questionnaire based on the International Index of Erectile Function (IIEF) 711/929. Seventy-seven percent of participants returned the questionnaire. Data from 668 (72%) respondents were included. Thirty-three percent (95%CI: 29.4-36.5%) had moderate/severe erectile dysfunction (EDF) and 24% (95%CI: 20.9-27.3%) had moderate to severe impairment of sexual desire. Variables significantly associated with EDF in multivariable analysis were older age (greater than 40 years), heterosexual status, non-alcohol drinking status, depression, antidepressants, psychotropic medications and duration of ARV therapy. Low sexual desire (LSD) was associated with older age (greater than 40 years), depression and black African ethnicity. We establish that EDF and LSD are common in both ARV naïve and ARV experienced, HIV-positive individuals. Erectile dysfunction was associated with long duration of ARV treatment, with a significantly increased risk of dysfunction in the quartile with the longest period of exposure. No significant association was seen with specific classes of anti-retrovirals. Older age, and depression were the variables most consistently associated with both EDF and LSD.
Collapse
Affiliation(s)
- D Asboe
- Directorate of HIV/GU Medicine, Chelsea and Westminster Hospital, London, UK.
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Gavazzi A, Bartoletti R. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med 2007; 4:1708-12. [PMID: 17655657 DOI: 10.1111/j.1743-6109.2007.00563.x] [Citation(s) in RCA: 189] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Sexual adverse experiences such as erectile dysfunction (ED), loss of libido, and ejaculation disorders have been consistent side effects of finasteride in a maximum percentage of 15% after 1 year of therapy. Such data could be seen as far from reality, if compared to a higher percentage that may be found in any common clinical practice. AIM This study aims to explain the dichotomy between literature's data and clinical practice data. METHODS One hundred twenty patients with a clinical diagnosis of benign prostatic hyperplasia (BPH), sexually active and with an International Index of Erectile Function-erectile function (IIEF-EF) domain >/=25 were randomized to receive finasteride 5 mg concealed as an "X compound of proven efficacy for the treatment of BPH" for 1 year with (group 2) or without (group 1) counseling on the drug sexual side effect. The phrase used to inform group 2 patients was ". . . it may cause erectile dysfunction, decreased libido, problems of ejaculation but these are uncommon". MAIN OUTCOME MEASURES The estimation of side effect was conducted at 6 and 12 months using the male sexual function-4 (MSF-4 item) questionnaire and a self-administered questionnaire. RESULTS One hundred seven patients completed the study. Group 2 patients (N = 55) reported a significant higher proportion of one or more sexual side effects as compared to group 1 (N = 52) (43.6% vs. 15.3%) (P = 0.03). The incidence of ED, decreased libido, and ejaculation disorders were 9.6, 7.7, and 5.7% for group 1, and 30.9, 23.6, and 16.3% for group 2, respectively (P = 0.02, P = 0.04, and P = 0.06). CONCLUSION In the current study, blinded administration of finasteride was associated with a significantly higher proportion of sexual dysfunction in patients informed on sexual side effects (group 2) as compared to those in which the same information was omitted (group 1) (P = 0.03). A scenario similar to group 2 of the current study is likely to occur in clinical practice, where the patient is counseled by the physician and has access to the drug information sheet. The burden of this nocebo effect (an adverse side effect that is not a direct result of the specific pharmacological action of the drug) has to be taken into account when managing finasteride sexual side effects.
Collapse
Affiliation(s)
- Nicola Mondaini
- UO Urology, S Maria Annunziata Hospital, University of Florence, Florence, Italy.
| | | | | | | | | | | | | |
Collapse
|
46
|
Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M. ORIGINAL RESEARCH—PSYCHOLOGY: Changes in Sexual Functioning Associated with Duloxetine, Escitalopram, and Placebo in the Treatment of Patients with Major Depressive Disorder. J Sex Med 2007; 4:917-29. [PMID: 17627739 DOI: 10.1111/j.1743-6109.2007.00520.x] [Citation(s) in RCA: 91] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
INTRODUCTION Depression and antidepressant therapy have been associated with sexual dysfunction in short-term and point-prevalence trials. AIM This report describes effects of duloxetine and escitalopram on sexual functioning during acute and long-term treatment of major depressive disorder (MDD). METHODS In this 8-month, double-blind, placebo-controlled study, adult outpatients with Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)-defined MDD were randomized to duloxetine 60 mg/day (N = 273; 173 female), escitalopram 10 mg/day (N = 274; 186 female), or placebo (N = 137; 87 female). After the first 8 weeks of treatment, dose increases were permitted to optimize treatment. MAIN OUTCOME MEASURE The 14-item Changes in Sexual Functioning Questionnaire (CSFQ) was used to assess sexual functioning. RESULTS Of the 114 patients who did not meet total CSFQ score criteria for global sexual dysfunction at baseline (duloxetine, N = 51; escitalopram, N = 39; placebo, N = 24), the incidence of treatment-emergent sexual dysfunction was significantly higher for escitalopram compared with placebo at 4 and 8 weeks, and significantly higher compared with duloxetine at 4 weeks. At 8 weeks, the incidence of treatment-emergent sexual dysfunction was 17/51 (33.3%) for duloxetine-treated patients; 19/39 (48.7%) for escitalopram-treated patients; and 4/24 (16.7%) for placebo-treated patients (P = 0.01 escitalopram vs. placebo; P = 0.13 duloxetine vs. placebo). After 12 weeks, no significant differences were observed between active drugs. At 8 months, the incidence of treatment-emergent sexual dysfunction was 33.3% for duloxetine, 43.6% for escitalopram, and 25.0% for placebo. Regardless of treatment, patients who achieved remission of MDD showed improvement in global sexual functioning, whereas worsening was observed for patients who did not achieve remission (P < 0.001). Discontinuation rates for sexual side effects did not differ between duloxetine (N = 2) and escitalopram (N = 7) (P = 0.07). CONCLUSIONS Short-term treatment demonstrated a higher incidence of treatment-emergent sexual dysfunction with escitalopram compared with duloxetine and placebo. After 12 weeks, there were no statistically significant differences between drugs; however, MDD outcome (regardless of treatment) had a significant impact on improvement in global sexual functioning.
Collapse
Affiliation(s)
- Anita Clayton
- Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, USA
| | | | | | | | | |
Collapse
|
47
|
Zourková A, Cesková E, Hadasová E, Ravcuková B. Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity. J Sex Marital Ther 2007; 33:343-55. [PMID: 17541852 DOI: 10.1080/00926230701385589] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
The aim of the study was to compare the distribution of therapeutic efficacy and sexual dysfunction during maintenance paroxetine treatment in 17 males and 38 females genotyped and phenotyped to determine their CYP2D6 metabolic status. Clinical results were monitored on scales Clinical Global Impression-Severity of Illness Scale (CGIS) and Arizona Sexual Experience Scale (ASEX). The phenotype procedure showed 7 males and 12 females with extensive metabolic status (EM) and 10 males and 26 females with poor metabolic status (PM). No variation in therapeutic efficacy between male and female subjects classified as PM and those marked as EM was found. A significantly higher rate of sexual dysfunction (p = 0.01) was recorded among females with a PM phenotype.
Collapse
|
48
|
Abstract
Psychotropic medication continues to be a central element in the care and treatment of people experiencing mental health problems. Nurses have a key role to play in patient education and in monitoring the benefits and side effects of prescribed drugs. However, evidence suggests that nurses tend to ignore or minimize side effects that impact on sexuality and sexual function. The focus of this article is on exploring the literature on psychotropic medication and sexual dysfunction.
Collapse
Affiliation(s)
- Agnes Higgins
- School of Nursing and Midwifery, Trinity College, Dublin
| |
Collapse
|
49
|
Abstract
In recent years, increased attention has been focused on antidepressant-associated sexual dysfunction, largely because of the widespread use of serotonin-specific reuptake inhibitors (SSRIs) and the recognition that such side effects can have a negative impact on treatment compliance. Data suggest that serotonergic antidepressants are associated with delayed ejaculation and anorgasmia, although these sexual problems are also linked to depression and to age. In this review, we discuss central mediators of normal orgasmic functioning and dysfunction, the relationship between depression and sexual dysfunction, possible mechanisms for SSRI-associated sexual dysfunction, and evolving treatment strategies.
Collapse
Affiliation(s)
- S Seidman
- Department of Psychiatry, Columbia University College of Physicians & Surgeons, New York, NY 10032, USA.
| |
Collapse
|
50
|
|